In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Relay Therapeutics (RLAY – Research Report), with a price target of $33.00. The company’s shares closed yesterday at $7.40.
According to TipRanks, Biegler is an analyst with an average return of -15.6% and a 24.29% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Fulcrum Therapeutics, Aptose Biosciences, and Day One Biopharmaceuticals.
Relay Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.
See today’s best-performing stocks on TipRanks >>
Based on Relay Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $119 thousand and a GAAP net loss of $98.51 million. In comparison, last year the company earned a revenue of $419 thousand and had a GAAP net loss of $62.05 million
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Relay Therapeutics (RLAY) Company Description:
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
Read More on RLAY:
- Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
- Relay Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors
- Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
